Full-Time
Posted on 5/14/2024
Develops treatments for eye care diseases
$158.2k - $221.6k/yr
Mid, Senior
Denver, CO, USA
Get referrals →
You have ways to get a Tarsus Pharamceuticals referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. Tarsus's products work by targeting specific medical conditions, and they have a pipeline of potential treatments for Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. What sets Tarsus apart from competitors is their commitment to addressing high unmet medical needs and their focus on specialized conditions. The company's goal is to improve patient outcomes by providing effective treatments and expanding their product offerings through research and strategic partnerships.
Company Size
201-500
Company Stage
IPO
Headquarters
Irvine, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...
Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).
Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.
IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.
Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.